X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
index medicus (11) 11
female (9) 9
aged (7) 7
male (7) 7
middle aged (7) 7
everolimus (6) 6
adult (5) 5
cancer (5) 5
urology & nephrology (5) 5
analysis (4) 4
carcinoma, renal cell - drug therapy (4) 4
care and treatment (4) 4
internal medicine (4) 4
kidney neoplasms - drug therapy (4) 4
kidney neoplasms - pathology (4) 4
retrospective studies (4) 4
adolescent (3) 3
aged, 80 and over (3) 3
antineoplastic agents - therapeutic use (3) 3
cost of illness (3) 3
economics (3) 3
health care sciences & services (3) 3
health policy (3) 3
health policy & services (3) 3
niacinamide - analogs & derivatives (3) 3
prognosis (3) 3
public health, environmental and occupational health (3) 3
sirolimus - analogs & derivatives (3) 3
sirolimus - therapeutic use (3) 3
sorafenib (3) 3
treatment outcome (3) 3
tyrosine kinase inhibitor (3) 3
tyrosine kinase inhibitors (3) 3
united states (3) 3
urology (3) 3
young adult (3) 3
2nd-line treatment (2) 2
axitinib (2) 2
carcinoma, renal cell (2) 2
carcinoma, renal cell - pathology (2) 2
carcinoma, renal cell - secondary (2) 2
child (2) 2
child, preschool (2) 2
consensus conference (2) 2
cost-effectiveness (2) 2
depression (2) 2
disease progression (2) 2
epidemiology (2) 2
growth factors (2) 2
health services - utilization (2) 2
health-related quality of life (2) 2
hematology, oncology and palliative medicine (2) 2
indoles - therapeutic use (2) 2
interferon-alpha (2) 2
kidney cancer (2) 2
management (2) 2
metastatic renal cell carcinoma (2) 2
neoplasm metastasis (2) 2
oncology (2) 2
overall survival (2) 2
pharmaceutical industry (2) 2
pharmacology & pharmacy (2) 2
protein kinase inhibitors - therapeutic use (2) 2
pyrroles - therapeutic use (2) 2
quality of life (2) 2
quality-adjusted life years (2) 2
randomized controlled-trial (2) 2
recommendations (2) 2
renal cell carcinoma (2) 2
research (2) 2
risk factors (2) 2
targeted therapies (2) 2
targeted therapy (2) 2
tuberous sclerosis (2) 2
tuberous sclerosis - complications (2) 2
tuberous sclerosis - therapy (2) 2
abdominal hysterectomy (1) 1
abnormal uterine bleeding (1) 1
adjuvant chemotherapy (1) 1
advanced renal cell carcinoma (1) 1
ambulatory blood pressure monitoring (1) 1
anemia (1) 1
angiogenesis inhibitors (1) 1
angiomyolipoma - complications (1) 1
angiomyolipoma - diagnosis (1) 1
angiomyolipoma - therapy (1) 1
anorexia (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
anxiety - epidemiology (1) 1
asian continental ancestry group (1) 1
benzenesulfonates - economics (1) 1
benzenesulfonates - therapeutic use (1) 1
blood pressure (1) 1
breast cancer (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - economics (1) 1
breast neoplasms - mortality (1) 1
burden (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Kidney Diseases, ISSN 0272-6386, 2012, Volume 60, Issue 5, pp. 812 - 820
Journal Article
Journal Article
Value in Health, ISSN 1098-3015, 2009, Volume 12, Issue 2, pp. 217 - 225
Abstract Objective Prophylaxis with granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN) in patients receiving... 
Internal Medicine | cost-effectiveness | breast cancer | pegfilgrastim | primary prophylaxis | cost‐effectiveness | Primary prophylaxis | Pegfilgrastim | Breast cancer | Cost-effectiveness | COLONY-STIMULATING-FACTOR | ADJUVANT CHEMOTHERAPY | DECISION-ANALYSIS | SINGLE-ADMINISTRATION PEGFILGRASTIM | INDUCED FEBRILE NEUTROPENIA | CELL LUNG-CANCER | MULTINATIONAL-ASSOCIATION | OUTPATIENT TREATMENT | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | DOSE-INTENSITY | ECONOMICS | DAILY FILGRASTIM | Breast Neoplasms - economics | Granulocyte Colony-Stimulating Factor - economics | United States | Humans | Middle Aged | Risk | Recombinant Proteins | Fever - chemically induced | Filgrastim | Fever - economics | Antineoplastic Agents - adverse effects | Neutropenia - mortality | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Decision Making | Quality-Adjusted Life Years | Primary Prevention - economics | Polyethylene Glycols | Risk Assessment | Risk Reduction Behavior | Risk Factors | Decision Support Techniques | Probability | Neutropenia - economics | Granulocyte Colony-Stimulating Factor - therapeutic use | Breast Neoplasms - drug therapy | Health Care Costs | Secondary Prevention - economics | Cost-Benefit Analysis | Neutropenia - prevention & control | Breast Neoplasms - mortality | Fever - prevention & control | Aged | Women | Oncology, Experimental | Health insurance industry | Research | Peptide hormones | Prevention | Chemotherapy | Granulocyte colony-stimulating factor | Analysis | Macrophage colony stimulating factor | Universities and colleges | Growth factors | Cancer
Journal Article
Journal Article
Value in Health, ISSN 1098-3015, 2011, Volume 14, Issue 6, pp. 846 - 851
Journal Article
Journal of human genetics, ISSN 1435-232X, 2018, Volume 64, Issue 2, pp. 113 - 125
Journal Article
Journal Article
Journal Article